We found for
Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

Bridging the Gap: Pathways for Regulatory and Health Technology Assessment of Histology Independent Therapies

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making
The Life Cycle of Pharmaceuticals: A Cross-National Perspective

Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison

Guidelines for the Economic Evaluation of Pharmaceuticals: Can the UK learn from Australia and Canada?
